Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) FCF Margin (2020 - 2026)

Cytek Biosciences filings provide 6 years of FCF Margin readings, the most recent being 7.68% for Q4 2025.

  • On a quarterly basis, FCF Margin fell 1101.0% to 7.68% in Q4 2025 year-over-year; TTM through Dec 2025 was 4.35%, a 1693.0% decrease, with the full-year FY2025 number at 4.35%, down 1693.0% from a year prior.
  • FCF Margin hit 7.68% in Q4 2025 for Cytek Biosciences, down from 2.98% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 25.72% in Q3 2024 to a low of 25.52% in Q2 2022.
  • Median FCF Margin over the past 5 years was 3.52% (2025), compared with a mean of 1.46%.
  • Biggest five-year swings in FCF Margin: soared 3732bps in 2024 and later crashed -2870bps in 2025.
  • Cytek Biosciences' FCF Margin stood at 6.63% in 2021, then soared by 39bps to 4.07% in 2022, then soared by 438bps to 13.76% in 2023, then crashed by -76bps to 3.34% in 2024, then tumbled by -330bps to 7.68% in 2025.
  • The last three reported values for FCF Margin were 7.68% (Q4 2025), 2.98% (Q3 2025), and 4.57% (Q2 2025) per Business Quant data.